Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
AC

NASDAQ · ACOG

Alpha Cognition Inc. Common Stock

Financial Services · Financial - Conglomerates

$8.40

Down-$0.40 (-4.55%)

Updated Sep 17, 2026, 3:28 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
89.13M
P/E ratio
-4.97
Dividend yield
0.00%
52-week range
$4.87 – $10.14
Volume
242.4K
Avg. volume
84.83K

Price performance

ACOG price history

1M range · 20 trading sessions · Daily adjusted prices

ACOG closed at $8.40 after 20 trading sessions, down 5.51% for the selected period.

Last close
$8.40
Period change
-5.51%
Period low
$8.40
Period high
$9.75
Daily close
View OHLC price history
ACOG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$8.82$8.92$8.30$8.40242.4K
Sep 15, 2026$8.61$8.94$8.34$8.80135.63K
Sep 14, 2026$8.88$8.88$8.50$8.71145.78K
Sep 11, 2026$8.99$9.30$8.65$8.9085.34K
Sep 10, 2026$8.93$9.34$8.86$8.9082.19K
Sep 9, 2026$9.54$9.54$8.915$9.1358K
Sep 8, 2026$9.31$9.75$9.1501$9.5285.41K
Sep 4, 2026$9.22$9.54$9.098$9.5245.94K
Sep 3, 2026$9.35$9.415$9.01$9.2190.8K
Sep 2, 2026$9.17$9.4199$9.06$9.31555.6K
Sep 1, 2026$9.24$9.4799$8.92$9.17171.32K
Aug 31, 2026$9.20$9.37$9.00$9.27215.62K
Aug 28, 2026$9.65$9.81$9.04$9.16137.21K
Aug 27, 2026$9.38$10.01$9.38$9.735155.57K
Aug 26, 2026$9.65$9.65$9.1642$9.41251.84K
Aug 25, 2026$9.80$9.865$9.3887$9.75220.14K
Aug 24, 2026$9.72$10.14$9.34$9.75168.46K
Aug 21, 2026$9.62$10.10$9.3601$9.75294.45K
Aug 20, 2026$9.19$9.9501$8.90$9.50360.39K
Aug 19, 2026$8.71$9.26$8.5301$8.89140.24K

Latest ACOG news

The latest Smart Investors Daily articles mentioning ACOG.

Stock researchCompany · Overview

ACOG research

Overview

Company profile and research snapshot.

Company profile

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
ACOG recent ratings
DateFirmRatingTarget
Aug 20, 2026B. Riley SecuritiesBuy—
Aug 17, 2026HC Wainwright & Co.Buy—
Jul 10, 2026Raymond JamesOutperform—
May 29, 2026Maxim GroupBuy—
May 22, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 25, 2026

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

VANCOUVER, British Columbia & GRAPEVINE, Texas, February 25, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By